Brokerages Set Precision BioSciences, Inc. (NASDAQ:DTIL) Price Target at $32.25

Precision BioSciences, Inc. (NASDAQ:DTIL) has earned an average rating of “Moderate Buy” from the five ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $32.25.

Several analysts have issued reports on the stock. Weiss Ratings raised shares of Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a research report on Wednesday, May 27th. JonesTrading restated a “buy” rating and issued a $30.00 target price on shares of Precision BioSciences in a research note on Friday, April 17th. Jefferies Financial Group reaffirmed a “buy” rating and set a $19.00 price target on shares of Precision BioSciences in a report on Friday, March 13th. Finally, Wall Street Zen upgraded shares of Precision BioSciences from a “sell” rating to a “hold” rating in a report on Saturday, March 14th.

Precision BioSciences Stock Up 0.3%

Shares of NASDAQ DTIL opened at $9.28 on Friday. The stock has a fifty day moving average price of $7.23 and a 200 day moving average price of $5.81. The company has a current ratio of 14.02, a quick ratio of 14.02 and a debt-to-equity ratio of 0.29. Precision BioSciences has a 12-month low of $3.53 and a 12-month high of $9.62. The company has a market cap of $239.42 million, a P/E ratio of -2.53 and a beta of 1.25.

Precision BioSciences (NASDAQ:DTIL) last announced its earnings results on Tuesday, May 5th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.09). The company had revenue of $10.84 million for the quarter, compared to analysts’ expectations of $4.05 million. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 85.37%. Research analysts anticipate that Precision BioSciences will post -2.21 EPS for the current fiscal year.

Institutional Trading of Precision BioSciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. HBK Sorce Advisory LLC acquired a new stake in shares of Precision BioSciences during the fourth quarter worth approximately $38,000. Engineers Gate Manager LP acquired a new stake in Precision BioSciences in the fourth quarter valued at $43,000. Occudo Quantitative Strategies LP acquired a new stake in Precision BioSciences in the fourth quarter valued at $52,000. Miller Financial Services LLC boosted its stake in Precision BioSciences by 50.0% during the 4th quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock valued at $62,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Precision BioSciences during the 3rd quarter valued at $84,000. 37.99% of the stock is owned by hedge funds and other institutional investors.

Precision BioSciences Company Profile

Precision BioSciences is a clinical?stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno?oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin?out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.